Which Cancers Have the Best Prognosis in Dogs?

Several canine cancers are genuinely curable, and a number of others can be managed for a long time with good quality of life. This gets far less attention than the aggressive cancers, and it leaves many owners more frightened than the situation warrants.

The best outcomes fall into two groups.

Cancers that can be cured outright. Low-grade mast cell tumors and low-grade soft tissue sarcomas that are completely removed at the first surgery frequently never return. Transmissible venereal tumor responds to a straightforward chemotherapy drug with complete response rates above 90%. Thyroid carcinoma that is still freely movable is often curable with surgery, with median survival measured in years. Most testicular tumors are resolved by neutering.

Cancers that are managed rather than cured, but managed well. B-cell multicentric lymphoma responds to chemotherapy in more than 80% of dogs, with many living a year or more feeling essentially normal. Chronic lymphocytic leukemia is often so slow-moving that monitoring, rather than treatment, is the right approach.

But the single most important point is this: what determines prognosis is usually not the cancer's name. It is whether the tumor is low grade, whether it was caught while still small and local, and whether the first surgery removed all of it. Those three things matter more than tumor type for most of the cancers dogs get — and the first two are partly within your control.

Key points

• Cure is a real word in veterinary oncology. For low-grade, completely excised tumors, many dogs live out their natural lives without recurrence.
• Low-grade mast cell tumors removed with clean margins carry an excellent outlook — reported recurrence-free rates of up to 90–100%, with median survival exceeding two years and often far longer.
• Transmissible venereal tumor is among the most treatable cancers in any species, with complete response reported in roughly 93% of dogs after four to six weekly vincristine treatments, rising to near 99% with eight.
• Freely movable thyroid carcinoma is often curable by surgery. One series of 144 dogs reported median survival of 802 days, with more than three-quarters living beyond 500 days.
• B-cell lymphoma is highly responsive, with remission achieved in most dogs and median survival typically around 10–12 months on standard protocols.
• Grade and margins matter more than tumor type. The same cancer can be curable or fatal depending on both.
• You cannot tell a benign lump from a malignant one by feel — which is exactly why aspirating early is the action that most improves outcomes.
• The first surgery is the best surgery. Recurrent tumors are harder to remove completely.

Detailed explanation

Two different kinds of good news

"Good prognosis" means two distinct things, and it helps to separate them.

Cured means the cancer is gone and is not expected to come back. This is realistic for many benign tumors and for low-grade malignant tumors that were completely removed.

Managed means the cancer is not eliminated but is controlled, often for a long time, with the dog feeling well. Lymphoma is the standard example. This is a genuinely good outcome even though it is not a cure, and it is worth not dismissing it as second-best.

Benign tumors — the largest group

Many of the lumps dogs develop are not cancer at all. Lipomas, sebaceous adenomas, histiocytomas, and various benign skin growths are common, particularly in older dogs, and carry an excellent outlook.

Cutaneous histiocytoma is worth singling out because it behaves unusually. It typically appears in young dogs as a fast-growing, raised, often reddened button-like lump — alarming to find, because rapid growth reads as a bad sign. It is benign, and it commonly regresses on its own over weeks to a few months without any treatment.

The essential caveat, and the reason this section does not end with reassurance: appearance and texture do not distinguish benign from malignant. A soft, movable lump that feels exactly like a fatty tumor can be something else. Mast cell tumors in particular imitate almost anything. The good news about benign tumors only becomes useful once a needle sample has established that a lump is one.

Low-grade mast cell tumors

Mast cell tumors have a fearsome reputation, and it is only half deserved. They span an unusually wide range of behavior, and the low-grade end has an excellent outlook.

Grading is done on a biopsy after removal. Two systems are used — the older Patnaik three-tier system and the Kiupel two-tier system introduced in 2011, which classifies tumors simply as low or high grade and has proven more reliable at predicting behavior. It is reasonable to ask that your pathologist report both.

For Kiupel low-grade tumors removed with clean margins, the outlook is very good. Reported figures include up to 90–100% never recurring, and median survival times exceeding two years, with many dogs living out their natural lives unaffected. One study of dogs with intermediate-grade tumors treated by surgery alone found 84% had no recurrence and only 5% developed metastasis, leading the authors to conclude that most such dogs do not need chemotherapy after complete excision.

The determining factors are grade and margins. Complete removal on the first attempt is what converts a mast cell tumor from a serious disease into a solved problem. If the pathology report shows incomplete margins, that is not failure — further options exist, including a second surgery or radiation to the site.

Low-grade soft tissue sarcomas

These tumors tend to be locally invasive but slow to spread. Low-grade soft tissue sarcomas removed with adequate margins have a low recurrence rate and generally do not require chemotherapy.

The challenge with these is local rather than systemic: they extend microscopic fingers into surrounding tissue beyond what can be felt, which is why margins are planned generously and why an initial "just take the lump off" approach can leave disease behind. Getting the first surgery planned properly — sometimes with imaging beforehand — is what makes the difference.

Transmissible venereal tumor

This one deserves to be better known, because it is among the most treatable cancers in any species.

Transmissible venereal tumor is a contagious cancer spread between dogs during mating, and it is endemic in many parts of the world though uncommon in areas with high rates of neutering. It usually appears as a cauliflower-like, often ulcerated and bleeding mass on the external genitalia.

Its response to treatment is remarkable. A recent systematic review found that weekly intravenous vincristine produced a complete response in about 93% of dogs after four to six sessions, rising to nearly 99% when extended to eight. Complete remission is anticipated in nearly all cases following recommended therapy.

Thyroid carcinoma — when it is still movable

Thyroid carcinoma sounds ominous and often is not, provided one condition is met: the tumor must still be freely movable rather than fixed to surrounding structures.

For mobile, non-metastatic tumors, surgical removal is the treatment of choice and the outlook is good. A study of 144 dogs undergoing thyroidectomy reported an overall median survival of 802 days, with 77% living beyond 500 days; historical figures for mobile tumors exceed three years.

The limitation is that only about 25–50% of canine thyroid tumors are still resectable at diagnosis, because of local invasiveness and proximity to critical structures. For fixed tumors, radiation and radioactive iodine remain options with median survivals reported up to 24 and 30 months respectively.

This makes thyroid carcinoma another argument for early investigation of a neck swelling.

Testicular and perianal tumors

Most canine testicular tumors are benign or low-grade, and neutering is typically curative. Perianal (hepatoid gland) adenomas — common in older intact male dogs — are hormone-responsive and generally resolve with neutering combined with removal.

These are worth knowing about because the treatment is straightforward and the outcome usually excellent.

B-cell lymphoma — the best example of "managed well"

Lymphoma is present throughout the body at diagnosis, which sounds like the worst possible starting point. Yet it is one of the most treatable cancers dogs get, because it responds so well to chemotherapy.

Combination protocols achieve remission in more than 80% of dogs. For B-cell lymphoma, median survival is typically around 300–365 days, and most dogs feel well during treatment — canine chemotherapy protocols are dosed to preserve quality of life rather than to maximize tumor kill, and severe side effects are uncommon.

Immunophenotyping matters here, because T-cell lymphoma behaves differently and carries a shorter expected survival. Knowing which one you are dealing with sets realistic expectations from the start.

Chronic lymphocytic leukemia

Some blood cancers are so indolent that treatment is not immediately warranted. Chronic lymphocytic leukemia in dogs is frequently discovered incidentally on routine bloodwork in an otherwise well dog, and monitoring rather than treating is often appropriate. Survival is commonly measured in years, and many affected dogs die of something else entirely.

This can be difficult to accept — being told your dog has leukemia and that the plan is to do nothing feels wrong. But active surveillance is a legitimate and evidence-based approach for indolent disease.

What the good-prognosis cancers have in common

Look across that list and a pattern emerges:

• They are accessible. Skin, mouth, testicle, thyroid — places where a tumor can be found early and physically removed.
• They are low grade. The cells still resemble normal tissue and behave predictably.
• They are caught local. No spread to lymph nodes or distant organs.
• They are completely removable, or highly responsive to a specific drug.

Two of those four — found early, caught local — are influenced by what happens at home and at routine appointments.

The single most useful thing you can do

Have lumps sampled rather than watched.

The widely used rule of thumb is that a skin mass the size of a pea or larger, or one present for a month, should be aspirated. It is quick, inexpensive, and usually needs no sedation.

Every one of the curable scenarios above depends on the tumor being found while it is still small, still local, and still completely removable. That window closes gradually and without any outward signal. Monitoring a lump feels cautious, and is in fact the decision that most often forecloses the best outcomes.

A note on how to hear a diagnosis

If your dog has just been diagnosed with cancer, the internet will show you the worst version of it. Search results skew toward the frightening, and the aggressive cancers generate more content than the curable ones.

The questions that actually determine your dog's outlook are specific: what type, what grade, what stage, and were the margins clean. Until you have those four answers, you do not yet know what you are dealing with — and for a substantial proportion of dogs, the answers are better than the fear that preceded them.

When to contact a veterinarian

Make an appointment within a few days if you notice:

• Any new lump the size of a pea or larger, or an existing lump that has changed in size, shape, or appearance
• A rapidly growing lump, particularly in a young dog — often a benign histiocytoma, but worth confirming
• A swelling in the neck region
• Firm swellings under the jaw, in front of the shoulders, or behind the knees
• A mass around the anus or on a testicle in an intact male dog
• A sore that has not healed within two weeks

Ask specifically about:

• Having the lump aspirated at that visit rather than at a follow-up
• Whether the sample will be read in-house or by a clinical pathologist
• Whether a mast cell tumor will be graded using both the Patnaik and Kiupel systems
• Whether the margins were complete, if a mass has already been removed

Ask for referral to a board-certified veterinary oncologist if:

• A mass is in a location where complete removal looks difficult
• Pathology shows incomplete margins
• You want to understand the full range of options before deciding

Questions to ask your veterinarian

• Can this lump be aspirated today?
• Based on the sample, does this look benign or malignant?
• If it is a mast cell tumor, what grade is it under both grading systems?
• Were the margins complete, and if not, what are the options?
• Is this a cancer where cure is realistic, or are we aiming to manage it?
• Has it spread, and what testing tells us that?
• If this is lymphoma, is it B-cell or T-cell?
• What would treatment involve day to day, and how would my dog feel during it?
• Is surgery likely to be curative on its own, or would we need anything afterward?
• What follow-up schedule would you recommend, and what am I watching for at home?

Sources

Christensen, J., Johnson, K., Ettinger, S., Garrett, L., Gordon, I., Ireifej, S., Love, A., & Wisecup, M. (2026). AAHA oncology guidelines for dogs and cats. Journal of the American Animal Hospital Association, 62(1), 1–37. https://doi.org/10.5326/JAAHA-MS-7549

American Animal Hospital Association. (2026). 2026 AAHA oncology guidelines for dogs and cats: Section 1. Overview of common cancers. https://www.aaha.org/resources/2026-aaha-oncology-guidelines-for-dogs-and-cats/section-1-overview-of-common-cancers/

dvm360. (2026). Take 5: Key points for managing cutaneous mast cell tumors in dogs. https://www.dvm360.com/view/take-5-key-points-managing-cutaneous-mast-cell-tumors-dogs

Kiupel, M., Webster, J. D., Bailey, K. L., et al. (2011). Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Veterinary Pathology, 48(1), 147–155.

Merck Veterinary Manual. (2024). Canine transmissible venereal tumor. https://www.merckvetmanual.com/reproductive-system/canine-transmissible-venereal-tumor/canine-transmissible-venereal-tumor

Morris Animal Foundation. (n.d.). Mast cell tumors in dogs: What research is revealing. https://www.morrisanimalfoundation.org/article/mast-cell-tumors-in-dogs

Veterinary and Comparative Oncology. (2025). Clinical guidelines for canine transmissible venereal tumour treatment: Systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/39805316/

Journal of Veterinary Internal Medicine. (2023). Thyroidectomy in dogs with thyroid tumors: Survival analysis in 144 cases (1994–2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061196/

Journal of the American Veterinary Medical Association. (2020). Outcomes for dogs with functional thyroid tumors treated by surgical excision alone. https://avmajournals.avma.org/view/journals/javma/256/4/javma.256.4.444.xml

Acta Veterinaria Scandinavica. (2022). Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743771/

Vets & Clinics. (2021). Canine mast cell tumours: Assessment, staging and surgical treatment. https://vetsandclinics.com/en/library/canine-mast-cell-tumours-assessment-staging-and-surgical-treatment

This article is for educational purposes only and is not a substitute for veterinary care. It cannot diagnose any condition in your dog or predict an individual outcome. Survival and cure rates describe groups of dogs studied under particular treatment conditions and cannot tell you what will happen to your own dog. Only microscopic examination of cells or tissue can determine whether a lump is benign or malignant — appearance and texture cannot. If you have found a lump on your dog, contact your veterinarian and ask whether it can be sampled.